- Home
- CHRS vs TCX Comparison
CHRS vs TCX Comparison
Compare CHRS & TCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TCX
- Stock Information
- Founded
- CHRS 2010
- TCX 1992
- Country
- CHRS United States
- TCX Canada
- Employees
- CHRS N/A
- TCX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TCX EDP Services
- Sector
- CHRS Health Care
- TCX Technology
- Exchange
- CHRS Nasdaq
- TCX Nasdaq
- Market Cap
- CHRS 159.2M
- TCX 193.9M
- IPO Year
- CHRS 2014
- TCX 1996
- Fundamental
- Price
- CHRS $1.35
- TCX $18.39
- Analyst Decision
- CHRS Strong Buy
- TCX
- Analyst Count
- CHRS 4
- TCX 0
- Target Price
- CHRS $4.51
- TCX N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- TCX 14.8K
- Earning Date
- CHRS 11-05-2025
- TCX 11-06-2025
- Dividend Yield
- CHRS N/A
- TCX N/A
- EPS Growth
- CHRS N/A
- TCX N/A
- EPS
- CHRS 1.55
- TCX N/A
- Revenue
- CHRS $272,209,000.00
- TCX $378,467,000.00
- Revenue This Year
- CHRS N/A
- TCX N/A
- Revenue Next Year
- CHRS $109.48
- TCX N/A
- P/E Ratio
- CHRS $0.87
- TCX N/A
- Revenue Growth
- CHRS 52.33
- TCX 7.88
- 52 Week Low
- CHRS $0.66
- TCX $13.27
- 52 Week High
- CHRS $2.43
- TCX $23.38
- Technical
- Relative Strength Index (RSI)
- CHRS 64.99
- TCX 48.57
- Support Level
- CHRS $1.23
- TCX $18.23
- Resistance Level
- CHRS $1.40
- TCX $19.24
- Average True Range (ATR)
- CHRS 0.08
- TCX 0.65
- MACD
- CHRS -0.00
- TCX 0.12
- Stochastic Oscillator
- CHRS 72.13
- TCX 67.56
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About TCX Tucows Inc.
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. Geographically company operates in USA, Canada and Europe.